

HAUSANSCHRIFT

Kurt-Georg-Kiesinger-Allee 3

53175 Bonn

TEL +49 (0)228 99 307-0 FAX +49 (0)228 99 307-5207

E-MAIL poststelle@bfarm.de

INTERNET www.bfarm.de

Per Postzustellungsurkunde

Clinuvel Europe Limited 10 Earlsfort Terrace D02 T380 **DUBLIN 2** Irland

Antrag vom 25.08.2021 auf Erteilung einer Gestattung gemäß §§ 10 Absatz 1a und 11 Absatz 1c Arzneimittelgesetz -

Einfuhr und Inverkehrbringen von SCENESSE 16 mg Implantat

Arzneimittelbezeichnung **SCENESSE 16 mg Implantat** Zulassungsinhaber **Clinuvel Europe Limited** Zulassungsnummer EU/1/14/969/001

Sehr geehrte Damen und Herren,

auf Ihren mit E-Mail vom 25. August 2021 gestellten Antrag ergeht der folgender

BESCHEID:

- 1. Es wird im Einzelfall gestattet, dass das o.g. Arzneimittel mit einer Kennzeichnung und Packungsbeilage in englischer Sprache in den Verkehr gebracht wird.
- 2. Diese Gestattung ist befristet bis zum 31. Oktober 2021.

Seite 2 von 3 Begründung:

Zu 1.

Nach §§ 10 Absatz 1a, 11 Absatz 1c AMG kann die zuständige Bundesoberbehörde im Fall eines drohenden oder bestehenden Versorgungsengpasses auf Antrag des Zulassungsinhabers im Einzelfall gestatten, dass das Arzneimittel befristet mit einer Kennzeichnung und Packungsbeilage in anderen als der deutschen Sprache in den Verkehr gebracht wird. Diese Voraussetzungen sind vorliegend erfüllt.

Bei der von Ihnen mit dem Antrag vorgelegten und für den US-amerikanischen Markt bestimmten englischsprachigen Kennzeichnung/Packungsbeilage handelt es sich um eine Kennzeichnung/Packungsbeilage in einer anderen als der deutschen Sprache.

Im Rahmen der durch das BfArM aktuell durchgeführten Sachverhaltsermittlung wurde ein drohender versorgungsrelevanter Lieferengpass festgestellt. Das Inverkehrbringen der in Rede stehenden Ware dient der Sicherstellung der Patientenversorgung.

Dieses Arzneimittel wird ausschließlich durch Ärzte unmittelbar an Patienten angewendet zur Prävention von Phototoxizität bei erwachsenen PatientInnen mit erythropoetischer Protoporphyrie (EPP). Scenesse hat einen Orphan Drug-Status. Wirkstoffgleiche Alternativen stehen daher nicht zur Verfügung, ebenso wenig wie therapeutische Alternativen.

Zu 2.

Die Befristung stützt sich auf §§ 10 Absatz 1a, 11 Absatz 1c AMG und ist im genannten Zeitraum erforderlich, um den drohenden Versorgungsengpass mit dem o. g. Arzneimittel auf dem deutschen Markt abzuwenden. Die Befristung wird bis zum 31.10.2021 ausgesprochen aufgrund der Bestätigung des Zulassungsinhabers, dass ab dem 01. 11.2021 die Verfügbarkeit von regulärer Ware in deutscher Aufmachung gewährleistet sein wird.

Hinweis:

Es wird empfohlen, aus Gründen der Nachvollziehbarkeit und Transparenz jeder Lieferung ein offizielles Informationsschreiben beizufügen.

$_{\text{Seite 3 von 3}} \ \underline{\text{Rechtsbehelfsbelehrung:}}$

Gegen diesen Bescheid kann innerhalb eines Monats nach Bekanntgabe Widerspruch erhoben werden. Der Widerspruch ist bei dem Bundesinstitut für Arzneimittel und Medizinprodukte (BfArM) in Bonn einzulegen.

Bonn, den 27. August 2021 Mit freundlichen Grüßen, Im Auftrag

Dr. Michael Horn

- Anlagen-
- Anlage 1 Vial Label für den US-amerikanischen Markt
- Anlage 2 Äußere Umhüllung für den US-amerikanischen Markt
- Anlage 3 Gebrauchsinformation für den US-amerikanischen Markt



FPS No: 36214

Customer Ref: PM0109 (USA VIAL LABEL)

CLINUVEL Customer Name :

Proof Number:

Artwork Created: 21 / 10 / 2020

Designer: Andrejus Plotnikovas

Product Size:

22.00 x 67.00 MM

Material: TBC

Material: Barcode No: 373372011616

Colours

1: PANTONE BLACK C

2: PANTONE 5535 C

Copy Position



Core Diameter: TBC Max Reel Diameter : TBC Qty per Reel : TBC

Backprint : TBC

Notes / Comments: Text minimum font size: 5.3pt. Part Number font size: 4pt. Clinuvel Logo font size: 5pt

Checked By: Wayne Barrett Date: 21 / 10 / 2020

Customer Approval

Signed: Date:

Please Ensure That You Check This Proof Carefully. It Is Important That You Check Size,Text, Barcodes & Pantone References As Your Label Will Be Produced According To Approval

ESSENTRA PACKAGING

129 Slaney Road, Dublin Industrial Estate, Glasnevin, Dublin 11, Ireland. Tel: +353 (0) 1 806 22 00. Fax: +353 (0) 1 806 22 98. www.essentra.com

36214_PM0109 NDC 73372-0116-1 **SCENESSE®** (afamelanotide) implant, 16 mg one implant per vial for subcutaneous use only CLINUVEL

Black 5535 Keyline 67.00 mm

22.00 mm

Edge Leading






FPS No : Customer Ref : PM0110 (USA CARTON) CLINUVEL Customer Name : Proof Number : Artwork Created: 22 / 09 / 2020 Designer: Andrejus Plotnikovas Product Size: 249.75 x 137.00 MM Material: TBC Material: N/A Barcode No: Colours PANTONE BLACK C PANTONE 5535 C 3: VARNISH Technical Non-Printable Colours FORM KEYLINE Notes / Comments: PHARMACODES FOR POSITION ONLY Text minimum font size: 7pt. Part Number font size: 5pt. Clinuvel Logo font size: 7pt Checked By: Wayne Barrett 22 / 09 / 2020 Date: Customer Approval Date: Please Ensure That You Check This Proof Carefully. It Is Important That You Check Size,Text, Barcodes & Pantone References As Your Label Will Be Produced According To Approval


ESSENTRA PACKAGINO

129 Slaney Road, Dublin Industrial Estate, Glasnevin, Dublin 11, Ireland. Tel: +353 (0) 1 806 22 00. Fax: +353 (0) 1 806 22 98. www.essentra.com



VARNISH LAYER VIEW

VARNISH CODE: V110



Andreius Plotnikovas

roduct Size: 237 x 360.00 MM Material: TBC Material: Barcode No N/A

Designer

Leaflet Front Leaflet Back PROCESS CYAN C 1: PROCESS BLACK C

PROCESS MAGENTA C PROCESS YELLOW C

PROCESS BLACK C

Technical Non-Printable Colours

KEYLINE

Notes / Comments: Text minimum Font size: 8pt Part Number Font size: 5pt

Checked By: Wayne Barrett 18 / 12 / 2020 Date:

Customer Approval

ease Ensure That You Check This Proof Carefully. It Is Important That u Check Size,Text, Barcodes & Pantone References As Your Label Will Produced According To Approval

Tel: +353 (0) 1806 22 00. Fax: +353 (0) 1806 22 98. www.essentra.com

HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SCENESSE safely and effectively. See full prescribing information for

SCENESSE® (afamelanotide) implant, for subcutaneous use Initial U.S. Approval: 2019

--INDICATIONS AND USAGE---SCENESSE is a melanocortin 1 receptor (MC1-R) agonist indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP). (1)

-- DOSAGE AND ADMINISTRATION--• SCENESSE should be administered by a healthcare professional who is

proficient in the subcutaneous implantation procedure and has completed training prior to administration. (2.1) Insert a single implant, containing 16 mg of afamelanotide, using an SFM Implantation Cannula or other implantation devices that have been determined by the manufacturer to be suitable for implantation of

SCENESSE. (2) • Administer SCENESSE subcutaneously every 2 months (2.1).

-----DOSAGE FORMS AND STRENGTHS--Implant: 16 mg of afamelanotide. (3)

---WARNINGS AND PRECAUTIONS----Skin monitoring: May induce darkening of pre-existing nevi and ephelides due to its pharmacological effect. A regular full body skin examination (twice yearly) is recommended to monitor all nevi and other skin

-- ADVERSE REACTIONS--The most common adverse reactions (incidence > 2%) are implant site reaction, nausea, oropharyngeal pain, cough, fatigue, dizziness, skin hyperpigmentation, somnolence, melanocytic nevus, respiratory tract

To report SUSPECTED ADVERSE REACTIONS, contact CLINUVEL INC. at 1-888-288-2031 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

See 17 for PATIENT COUNSELING INFORMATION

infection, non-acute porphyria, and skin irritation (6).

Revised: 03/2020

FULL PRESCRIBING INFORMATION: CONTENTS*

INDICATIONS AND USAGE

2 DOSAGE AND ADMINISTRATION 2.1 Important Dosage and Administration Information 2.2 Instructions for Implantation of SCENESSE

3 DOSAGE FORMS AND STRENGTHS 4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Skin Monitoring 6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

8 USE IN SPECIFIC POPULATIONS 8.1 Pregnancy

8.2 Lactation 8.4 Pediatric Use 8.5 Geriatric Use 11 DESCRIPTION

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action 12.2 Pharmacodynamics 12.3 Pharmacokinetics

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility 14 CLINICAL STUDIES

16 HOW SUPPLIED/STORAGE AND HANDLING 17 PATIENT COUNSELING INFORMATION

* Sections or subsections omitted from the full prescribing information

FULL PRESCRIBING INFORMATION

1 INDICATIONS AND USAGE

SCENESSE® is indicated to increase pain free light exposure in adult patients with a history of phototoxic reactions from erythropoietic protoporphyria (EPP).

2 DOSAGE AND ADMINISTRATION

2.1 Important Dosage and Administration Information

SCENESSE should be administered by a health care professional. All healthcare professionals should be proficient in the subcutaneous implantation procedure and have completed the training program provided by CLINUVEL prior to administration of the SCENESSE implant *[see* Dosage and Administration (2.2)]. Additional information, including a video, is available at http://www.clinuvel.com/US-HCP. The additional information has not been evaluated or approved by the FDA.

A single SCENESSE implant is inserted subcutaneously above the anterior supra-iliac crest every 2 months.

Use the SFM Implantation Cannula to implant SCENESSE. Contact CLINUVEL INC. for other implantation devices that have been determined by the manufacturer to be suitable for implantation of

Maintain sun and light protection measures during treatment with SCENESSE to prevent phototoxic reactions related to EPP.

2.2 Instructions for Implantation of SCENESSE

Insert a single SCENESSE implant (containing 16 mg of afamelanotide) subcutaneously above the anterior supra-iliac crest.

Implant SCENESSE observing an aseptic technique. The following equipment is needed for the implant insertion:

SCFNESSE implant

- SFM Implantation Cannula; use of a device that has not been determined to be suitable could result in damage to the SCENESSE implant [see Dosage and Administration (2.1)].
- Sterile aloves
- Local anesthetic, needle and syringe • Blunt forceps suitable for removing the SCENESSE implant from the
- · Sterile gauze, adhesive bandage, pressure bandage

glass vial and placement of the SCENESSE implant

Step 6 Apply pressure to the site of the implant while removing the stylet (obturator) and the cannula. Verify that no implant or implant portion remains in the cannula.

 Take the carton containing SCENESSE out of the refrigerator to allow the product to gradually warm up to ambient temperature.

Step 2

the skin surface.

Step 3 (optional)

Put the patient in a comfortable

insertion site 3-4 cm above the

Anesthetize the area of insertior (puncture) if deemed necessary and in

consultation with the patient.

While pinching the skin of the

Step 5

precautions

insertion site, insert the cannula with

the bevel facing upwards (away from

the abdomen) at a 30-45° angle into

the subcutaneous laver. Advance the

cannula 2 cm into the subcutaneous

Remove the stylet (obturator) from

the cannula maintaining aseptic

Load the implant into the cannula

Using the stylet (obturator) gently

push the implant down the full

length of the cannula's shaft

reclined supine position. Identify the

anterior supra-iliac crest and disinfect

 Remove the seal and stopper from the glass vial containing SCENESSE. Remove the implant from the vial using the blunt forceps under aseptic conditions and place the implant on a sterile gauze.



Verify the correct insertion and placement of the implant by palpating the skin overlying the implant.



Step 8 Apply dressing to the insertion site. Leave dressing in place for 24 hours.



Monitor the patient for 30 minutes after the implant administration.

3 DOSAGE FORMS AND STRENGTHS

Implant: 16 mg of afamelanotide as a solid white to off-white bioresorbable, sterile rod approximately 1.7 cm in length and 1.45 mm in

4 CONTRAINDICATIONS

5 WARNINGS AND PRECAUTIONS

5.1 Skin Monitoring

SCENESSE may lead to generalized increased skin pigmentation and darkening of pre-existing nevi and ephelides because of its pharmacologic effect. A full body skin examination (twice yearly) is recommended to monitor pre-existing and new skin pigmentary lesions.

6 ADVERSE REACTIONS

6.1 Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The safety of SCENESSE was evaluated in 3 randomized, multicenter, prospective, vehicle controlled clinical trials (Study CUV029, Study CUV030, and Study CUV039) involving 244 adult subjects with ervthropoietic protoporphyria (EPP) without significant liver involvement. Subjects received subcutaneous SCENESSE implants containing 16 mg of afamelanotide every 2 months. A total of 125 subjects received SCENESSE and 119 subjects received vehicle implants.

Cyan Magenta Yellow Black Keyline

360 mm

xxxxx_PM0128_bk

Table 1 summarizes the adverse reactions that occurred in more than 2%

Table 1: Adverse Reactions Occurring in More Than 2% of Subjects with EPP Through Month 6 (Studies CUV039, CUV030, and CUV029)

Adverse Reaction	SCENESSE n (%) N = 125	Vehicle n (%) N = 119
Implant site reaction ¹	26 (21%)	12 (10%)
Nausea	24 (19%)	17 (14%)
Oropharyngeal pain	9 (7%)	6 (5%)
Cough	8 (6%)	4 (3%)
Fatigue	7 (6%)	3 (3%)
Skin hyperpigmentation ²	5 (4%)	0 (0%)
Dizziness	5 (4%)	4 (3%)
Melanocytic nevus	5 (4%)	2 (2%)
Respiratory tract infection	5 (4%)	3 (3%)
Somnolence	3 (2%)	1 (1%)
Non-acute porphyria	2 (2%)	0 (0%)
Skin irritation	2 (2%)	0 (0%)

1: Implant site reaction includes: implant site bruising, discoloration, erythema. hemorrhage, hypertrophy, irritation, nodule, pain, pruritus, swelling; injection site bruising and erythema; and expelled implant.

²: Skin hyperpigmentation includes skin hyperpigmentation, pigmentation lip (subject also had skin hyperpigmentation), and pigmentation disorder.

Specific Adverse Reactions

Implant Site Reactions: Implant site reactions were more common in the SCENESSE group (21%) compared to the vehicle group (10%). In the SCENESSE group, the most common implant site reaction was implant site discoloration (10%).

8 USE IN SPECIFIC POPULATIONS

8.1 Pregnancy Risk Summary

There are no data on SCENESSE use in pregnant women to evaluate for any drug associated risk of major birth defects, miscarriage, or adverse maternal or fetal outcome.

In animal reproductive and development toxicity studies, no adverse developmental effects were observed with afamelanotide administration during the period of organogenesis to pregnant rats at subcutaneous doses up to 12 times the maximum recommended human dose (MRHD) (see

All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2% to 4% and 15% to 20%, respectively.

Animal Data

In embryofetal development studies in Sprague Dawley and Lister Hooded

rats, afamelanotide was administered subcutaneously to pregnant rats at doses of 0.2, 2, or 20 mg/kg/day throughout the period of organogenesis. No adverse embryofetal developmental effects were observed at doses up to 20 mg/kg/day (12 times the MRHD, based on a body surface area comparison).

In a pre- and post-natal development study in Sprague Dawley rats, afamelanotide was administered subcutaneously at doses of 0.2. 2. or 20 mg/kg/day during the period of organogenesis through lactation. No treatment-related effects were observed at doses up to 20 mg/kg/day (12 times the MRHD, based on a body surface area

8.2 Lactation

Risk Summary

There are no data on the presence of afamelanotide or any of its metabolites in human or animal milk, the effects on the breastfed infant, or the effect on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother's clinical need for SCENESSE and any potential adverse effects on the breastfed. infant from SCENESSE or from the underlying maternal condition.

8.4 Pediatric Use The safety and effectiveness of SCENESSE have not been established in pediatric patients.

8.5 Geriatric Use

There were 10 subjects 65 years old and over in the clinical studies for EPP [see Clinical Studies (14)]. Of the 125 subjects treated with SCENESSE in these studies, 4 (3%) were 65 years of age and older. Clinical studies of SCENESSE did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

11 DESCRIPTION

SCENESSE (afamelanotide) implant is a controlled-release dosage form for subcutaneous administration. Afamelanotide is a melanocortin 1 receptor (MC1-R) agonist. The active ingredient afamelanotide acetate is a synthetic peptide containing 13 amino acids with molecular formula $C_{78}H_{111}N_{21}O_{19} \bullet xC_2H_4O_2$ (3 $\leq x \leq 4$). The molecular weight of afamelanotide is 1646.85 (anhydrous free base). Afamelanotide acetate has the following structure:

Ac-Ser-Tyr-Ser-Nle-Glu-His-(D)Phe-Arg-Trp-Gly-Lys-Pro-Val-NH,• xCH3COOH.

Afamelanotide is a white to off-white powder, freely soluble in water. Each SCENESSE implant contains 16 mg of afamelanotide (equivalent to 18 mg of afamelanotide acetate), and 15.3-19.5 mg of poly (DL-lactide-co-glycolide). SCENESSE implant is a single, solid white to off-white, bioresorbable and sterile rod approximately 1.7 cm in length and 1.45 mm in diameter. The implant core comprises of the drug substance admixed with a poly (DL-lactide-co-glycolide) bioresorbable copolymer.

12 CLINICAL PHARMACOLOGY

12.1 Mechanism of Action

Afamelanotide is a synthetic tridecapeptide and a structural analog of α -melanocyte stimulating hormone (α -MSH). Afamelanotide is a melanocortin receptor agonist and binds predominantly to MC1-R.

12.2 Pharmacodynamics

Afamelanotide increases production of eumelanin in the skin independently of exposure to sunlight or artificial UV light sources.

12.3 Pharmacokinetics

The pharmacokinetics of afamelanotide following administration of a single subcutaneous implant of SCENESSE were evaluated in 12 healthy adults. High variability was observed in the plasma concentrations of afamelanotide and for most subjects (9 out of 12), the last measurable afamelanotide concentration was at 96 hours post-dose. The mean \pm SD C_{max} and AUC_{0-inf} were 3.7 \pm 1.3 ng/mL and 138.9 \pm 42.6 hr*ng/mL,

<u>Absorption</u> The median Tmax was 36 hr.

The apparent half-life of afamelanotide is approximately 15 hr when administered subcutaneously in a controlled release implant.

Afamelanotide may undergo hydrolysis. However, its metabolic profile has not been fully characterized.

Specific Populations

The effect of renal or hepatic impairment on the pharmacokinetics of afamelanotide is unknown

Drug Interaction Studies

No drug interaction studies were conducted with afamelanotide.

13 NONCLINICAL TOXICOLOGY

13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility Carcinogenicity studies have not been conducted with SCENESSE.

assay, and in vivo mouse bone marrow micronucleus assay. No effects on male or female fertility and reproductive performance were observed in rats at subcutaneous doses up to 20 mg/kg/day afamelanotide (12 times the MRHD, based on a body surface area

Afamelanotide was negative in the Ames test, in vitro mouse lymphoma

14 CLINICAL STUDIES

comparison).

Three vehicle-controlled, parallel-group clinical trials of SCENESSE were conducted in subjects with EPP. Of these trials, two trials (Study CUV039, NCT 01605136, and Study CUV029, NCT 00979745) were designed to assess exposure to direct sunlight on days with no phototoxic pain. The two trials differed in the number of days of follow-up, the time windows within a day in which time spent outdoors was recorded, and how the amount of time spent in direct sunlight on each day was characterized. The subjects enrolled in these trials were primarily Caucasian (98%), the mean age was 40 years (range 18 to 74 years), and 53% of subjects were male and 47% were female

Study CUV039 enrolled 93 subjects, of whom 48 received SCENESSE (16 mg of afamelanotide administered subcutaneously every 2 months) 45 received vehicle. Subjects received three implants and were followed for 180 days. On each study day, subjects recorded the number of hours spent in direct sunlight between 10 am and 6 pm, the number of hours spent in shade between 10 am and 6 pm, and whether they experienced any phototoxic pain that day. The primary endpoint was the total number

of hours over 180 days spent in direct sunlight between 10 am and 6 pm on days with no pain. The median total number of hours over 180 days spent in direct sunlight between 10 am and 6 pm on days with no pain was 64.1 hours for subjects receiving SCENESSE and 40.5 hours for subjects receiving vehicle.

Study CUV029 enrolled 74 subjects, of whom 38 received SCENESSE (16 g of afamelanotide administered subcutaneously every 2 months), 36 received vehicle. Subjects received five implants and were followed for 270 days. On each study day, subjects recorded the number of hours spent outdoors between 10 am and 3 pm, whether "most of the day" was spent in direct sunlight, shade, or a combination of both, and whether they experienced any phototoxic pain that day. The primary endpoint was the total number of hours over 270 days spent outdoors between 10 am and 3 pm on days with no pain for which "most of the day" was spent in direct sunlight. This analysis does not include sun exposure on days for which subjects reported spending time in a combination of both direct sunlight and shade. The median total number of hours over 270 days spent outdoors between 10 am and 3 pm on days with no pain for which "most of the day" was spent in direct sunlight was 6.0 hours for subjects in the

SCENESSE group and 0.75 hours for subjects in the vehicle group.

16 HOW SUPPLIED/STORAGE AND HANDLING

SCENESSE (afamelanotide) implant, 16 mg, for subcutaneous administration (NDC 73372-0116-1) is supplied in a Type I amber glass vial sealed with a PTFE coated rubber stopper. Each vial contains one afamelanotide implant and is packaged individually in a cardboard box. SCENESSE implant is a solid white to off-white, bioresorbable and sterile rod approximately 1.7 cm in length and 1.45 mm in diameter. Store in a refrigerator at 2°C - 8°C (36°F-46°F). Protect from light. SCENESSE implants are not supplied with an implantation device for

17 PATIENT COUNSELING INFORMATION

Concomitant Measures Advise patients to maintain sun and light protection measures during treatment with SCENESSE to prevent phototoxic reactions related to EPP.

Advise patients that darkening of pre-existing nevi and ephelides may occur

subcutaneous administration [see Dosage and Administration (2)].

with use of SCENESSE. A full body skin examination is recommended twice yearly to monitor pre-existing and new skin pigmentary lesions. Expelled Implant

Advise patients to contact their healthcare provider if the implant is expelled.

Dressing removal Advise patients that the dressing can be removed after 24 hours.

Insertion Site Care and Monitoring Advise patients to monitor the insertion site after dressing removal and to report any reaction observed at the site to their healthcare provider.

Manufactured for:

CLINUVEL. INC. Burlingame, CA 94010 CLINUVEL

Black Keyline 360 mm